Orlistat (Xenical)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fatty Liver
Conditions
Fatty Liver, Hepatitis
Trial Timeline
Oct 1, 2003 → Dec 1, 2006
NCT ID
NCT00160407About Orlistat (Xenical)
Orlistat (Xenical) is a approved stage product being developed by Roche for Fatty Liver. The current trial status is completed. This product is registered under clinical trial identifier NCT00160407. Target conditions include Fatty Liver, Hepatitis.
What happened to similar drugs?
5 of 11 similar drugs in Fatty Liver were approved
Approved (5) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160407 | Approved | Completed |
Competing Products
20 competing products in Fatty Liver
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 29 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 19 |
| GODEX + Placebo | Celltrion | Phase 3 | 47 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 35 |
| AZ compound | AstraZeneca | Phase 2 | 27 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 29 |
| metformin | Merck | Phase 2/3 | 34 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 35 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 29 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 35 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 27 |
| LJN452 | Novartis | Phase 1 | 29 |
| LCQ908 + placebo | Novartis | Phase 2 | 35 |
| Xenical, Pegasys, Copegus | Roche | Approved | 43 |
| Placebo + RO5093151 | Roche | Phase 1 | 29 |
| AMG 609 + Placebo | Amgen | Phase 1 | 29 |
| Glucagon | Novo Nordisk | Pre-clinical | 26 |
| Blood samples | Novo Nordisk | Pre-clinical | 18 |
| NNC0194-0499 + NNC0194-0499 + NC0194-0499 | Novo Nordisk | Phase 1 | 29 |